相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia
Ing S. Tiong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial
Ephraim J. Fuchs et al.
BLOOD (2021)
Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT
J. Loke et al.
BONE MARROW TRANSPLANTATION (2021)
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
Long-Term Follow up of BMT CTN 0901, a Randomized Phase III Trial Comparing Myeloablative (MAC) to Reduced Intensity Conditioning (RIC) Prior to Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) (MAvRIC Trial)
Bart L. Scott
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Stefan O. Ciurea et al.
BLOOD (2020)
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon et al.
BLOOD (2020)
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia
Jack Ghannam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
Justin Loke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party
Jean El-Cheikh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Dietrich Wilhelm Beelen et al.
LANCET HAEMATOLOGY (2020)
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Rohtesh S. Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Tobias Herold et al.
LEUKEMIA (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan et al.
LANCET ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Betul Oran et al.
BLOOD ADVANCES (2020)
The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
Jakob R. Passweg et al.
BONE MARROW TRANSPLANTATION (2019)
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolanos-Meade et al.
LANCET HAEMATOLOGY (2019)
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Mark J. Levis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Olle Ringden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
Giorgia Battipaglia et al.
BLOOD (2019)
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR
Jason Dehn et al.
BLOOD (2019)
Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT
Annalisa Ruggeri et al.
BONE MARROW TRANSPLANTATION (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Charles C. Bell et al.
NATURE COMMUNICATIONS (2019)
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G. Ruecker et al.
BLOOD (2019)
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
Andrew H. Wei et al.
BLOOD (2019)
Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources
Mahmoud Elsawy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Aviva C. Krauss et al.
CLINICAL CANCER RESEARCH (2019)
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Christina Rautenberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Mareike Frick et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
The growing landscape of FLT3 inhibition in AML
Catherine C. Smith
Hematology-American Society of Hematology Education Program (2019)
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Sarah Cooley et al.
BLOOD ADVANCES (2019)
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation
Max Jan et al.
BLOOD ADVANCES (2019)
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
Francesco Saraceni et al.
ONCOTARGET (2018)
Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most
Bronwen E. Shaw et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
Mithun Vinod Shah et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation
Lea Sellmann et al.
BONE MARROW TRANSPLANTATION (2018)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Bjorklund et al.
CLINICAL CANCER RESEARCH (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
Frederick Fasslrinner et al.
LANCET HAEMATOLOGY (2018)
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
E. J. Duncavage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Acute myeloid leukemia: 2019 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
Uday R. Popat et al.
LANCET HAEMATOLOGY (2018)
Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML
Richard Thomas T. Maziarz et al.
BLOOD (2018)
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse
TaeHyung Kim et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kroeger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
F. M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
M. T. Voso et al.
ANNALS OF ONCOLOGY (2017)
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Jurjen Versluis et al.
BLOOD ADVANCES (2017)
Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants
B. E. Shaw et al.
BONE MARROW TRANSPLANTATION (2017)
Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT
Rebecca A. Marsh et al.
BLOOD (2016)
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy
Craig Kollman et al.
BLOOD (2016)
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia
Gert J. Ossenkoppele et al.
HAEMATOLOGICA (2016)
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia
Gert J. Ossenkoppele et al.
HAEMATOLOGICA (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Y. Zhou et al.
LEUKEMIA (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Lynn Quek et al.
BLOOD ADVANCES (2016)
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes
Hans C. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research
Michael R. Verneris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Roni Shouval et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi et al.
LANCET ONCOLOGY (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia
J. Loke et al.
ANNALS OF HEMATOLOGY (2015)
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study
E. Nikolousis et al.
BONE MARROW TRANSPLANTATION (2015)
Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
Erica D. Warlick et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of Transplant
Fotios V. Michelis et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
Yu Wang et al.
BLOOD (2014)
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the US Registry
Loren Gragert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
Nona Shayegi et al.
BLOOD (2013)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
Christopher Bredeson et al.
BLOOD (2013)
Randomized Study of 2 Reduced-Intensity Conditioning Strategies for Human Leukocyte Antigen-Matched, Related Allogeneic Peripheral Blood Stem Cell Transplantation Prospective Clinical and Socioeconomic Evaluation
Didier Blaise et al.
CANCER (2013)
Donor Lymphocyte Infusion Induces Polyspecific CD8+ T-Cell Responses With Concurrent Molecular Remission in Acute Myeloid Leukemia With NPM1 Mutation
Susanne Hofmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-
Jan M. Middeke et al.
BLOOD (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
Katja Sockel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation
Marcelo C. Pasquini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories
Jan J. Cornelissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?
Farhad Ravandi et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
Martin Bornhaeuser et al.
LANCET ONCOLOGY (2012)
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study
Katharina Fleischhauer et al.
LANCET ONCOLOGY (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Jan J. Cornelissen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Robert J. Soiffer et al.
BLOOD (2011)
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
Claudio G. Brunstein et al.
BLOOD (2011)
Independent prognostic variables in acute myeloid leukaemia
Matthew L. Smith et al.
BLOOD REVIEWS (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia
Jaime Sanz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution
Ronjon Chakraverty et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine
M. Wermke et al.
LEUKEMIA (2010)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
K. C. S. Queiroz et al.
ONCOGENE (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M. Pagel et al.
BLOOD (2009)
Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
Alois Gratwohl et al.
CANCER (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
Mohamed L. Sorror et al.
BLOOD (2007)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Nonmyeloablative transplantation with or without alemtuzumab:: comparison between 2 prospective studies in patients with lymphoproliferative disorders
JA Pérez-Simón et al.
BLOOD (2002)
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)
A Bacigalupo et al.
BLOOD (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens:: Impact of pretransplantation and posttransplantation factors on outcome
M Michallet et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.
MJ Laughlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
